Summary A recently developed enzyme assay, utilizing ['251]-iododeoxyuridine as substrate, and capable of detecting normal levels of serum deoxythymidine kinase (s-dTk), was used in an investigation of sera from 155 untreated patients with non-Hodgkin's lymphoma (NHL). The patients were classified at the discovery of disease, both according to spread (stages I-IV according to the Ann Arbor classification) and to tumour histology (the Kiel classification). The results showed a significant correlation between s-dTk level and the extent of disease, as well as to the malignancy; i.e. the more advanced the disease or the more aggressive the tumour, the higher the s-dTk values. Greater than 100-fold increases in s-dTk levels were found in some patients compared to those reported for healthy individuals. A high pretreatment level of s-dTk for patients in stages III-IV correlated with a poor prognosis for the patient in terms of survival. This was consistent even when only patients in stages III-IV with "high-grade" malignant lymphomas were included in the analysis. Longitudinal studies of s-dTk levels in 19 NHL patients showed that s-dTk increases with progression of the disease, decreases during successful therapy, and finally increases during relapse. It is concluded that s-dTk could be used both as a prognostic marker and to monitor the effect of therapy in NHL patients.
Three different isoenzymes of deoxythymidine kinase (dTk) (ATP:thymidine 5'-phosphotransferase (EC 2.7.1.21)) have been found in human cells (Kit; 1979) . One of these, dTK-F, the cytosolar dTk, occurs in high amounts in dividing cells (stages Gi -.S) and is more or less absent in resting differentiated cells (Bello, 1974) . For this reason dTk activity has been studied in relation to tumor cell growth, employing different animal systems (Bresnick et al., 1969 , 1973 . Studies of 23 matched human neoplastic and normal tissue pairs showed higher dTk activity in tumours, except for bronchogenic carcinomas and hypernephromas (Gordon et al., 1968) . Recent reports have demonstrated enhanced dTk-F levels in peripheral blood lymphocytes of some patients suffering from non-Hodgkin's lymphoma (NHL) or active chronic lymphocytic leukaemia (Ellims et al., 1981a; Ellims, 1981; Kreis et al., 1982) . These investigators, although using an enzyme assay with radiolabelled dT as substrate, were able to find dTk-F in the serum of 26 patients with advanced NHL. By comparing these patients with other patients having mainly dTk-A (the mitochondrial isoenzyme) levels a significant difference in median survival time was found i.e. dTk-F positive patients had a short survival time (Ellims et al., 1981b ).
An optimized dTk assay suitable for the detection of viral dTk isoenzymes based on the use of [12 1]-iododeoxyuridine (IUdR) as the substrate has been presented (Gronowitz & Kdllander; . A different assay system, still based on the use of [125I] -IUdR, as the substrate, optimized to measure dTk-F was recently developed (Gronowitz et al., submitted) . By the use of this method normal serum-dTk levels (s-dTk) could be measured and transiently enhanced s-dTk levels were found during acute-convalescent stage of infections with morbilli, rubella and different herpesviruses. Elevated s-dTk levels, were also found to be characteristic of pernicious anaemia and of different malignancies, such as chronic granulocytic leukaemia, acute myelocytic and lymphocytic leukaemia, small cell lung cancer, and nonHodgkin's lymphoma (NHL) (Gronowitz et al., submitted) .
The aim of the present study was to correlate s-dTk levels of patients with NHL to other parameters, such as spread, grade of malignancy, and to therapic effects, in order to evaluate s-dTK as a prognostic and diagnostic serum marker.
Materials and methods Enzyme assay
The assay utilizes [125I]-IUdR (final concentration 10-7 M, 130-160CimM)-1, as substrate, and is described in detail elsewhere (Gronowitz et al., submitted) . This new assay system gives a linear turnover of substrate for the cellular dTk-F for more than 2 h. In order to minimize fluctuations in the assay, a biological control for the isotope was utilized, and all values were recalculated to units (Gronowitz et al., submitted) . Under the conditions used 1 unit of enzyme is equal to an enzyme activity of 1.2 10 '" katal, and gives I1000cpm, with the amount of isotope used. The average s-dTk level in healthy subjects is estimated to be 2.5 units l1l-' (s.d. 1.25) (Gronowitz et al., submitted (GerardMarchant et al., 1974) . In the original classification there are 2 prognostic subgroups, but recently 3 prognostic subgroups were recognized in the region studied (Glimelius & Sundstrom; 1982) . These results have been applied in the present investigation. The distribution of the patients is shown in Table I , which also gives the different histological types of each group and their abbreviations. The criteria for staging adopted at the Ann Arbor symposium on Hodgkin's disease was used (Carbone et al., 1971 Pretreatment s-dTk level in relation to survival A discriminant analysis of pretreatment s-dTk levels for patients in stages III-IV, in relation to survival time was carried out. The results showed that the best discriminating level was 10 units, giving a highly significant difference in survival time (P<0.001) between the 2 groups. The patients with the low s-dTk values had an actuarial survival of 85% at the 32nd month compared to <30% for those with levels above 10 units ( Figure 3a ). As it is well known that the grade of malignancy influences survival, we also compared s-dTK levels with survival time for patients with "high grade" malignancy in stages III-IV. A significant difference was still found (P< 0.02), with patients having pretreatment s-dTk > 10 units dying sooner ( Figure  3b ). (Number in parenthesis indicates remaining individuals at observation after 32 months). II IV   IV  IV  IV  IV  IV  IV  III  IV  IV  IV  IV  IV Figure 4 shows that a rapid fall in s-dTk was observed after splenectomy as examplified in 2 patients. Three patients in stage I or II with low s-dTk, treated initially only with local radiotherapy and having elevated s-dTk at relapse are shown in Figure 5 . All 3 received chemotherapy during relapse, and in two of them s-dTk was measured after chemotherapy was given. Patient MO responded to the therapy and s-dTk was found to decrease, whereas HH did not respond and s-dTk remained unchanged.
The remaining 14 patients were all in stage III or IV when therapy was started. Five of them did not respond to the initial treatment, and, 3 died without any improvement ( Figure 6a) ; as seen in Figures 6a and 7a , progression of the disease was accompanied by increasing s-dTk. The other 2 responded and underwent temporary improvement when given a different therapy; s-dTk mirrored this clinical course by a temporary decrease followed by continued increase (Fig. 7a) .
Four patients were considered to be in partial remission after 6 months of treatment, and their s-dTk levels were found to decrease, but not to normality ( Figure 6b , and 2 patients in Figure 7b) .
Two of these relapsed and increasing s-dTk levels ensued (Figure 7b) .
Finally, 5 patients went into complete remission, which was followed by normalization of s-dTk ( Figure 6c , and patient GE in Figure 7b ). Ope of them relapsed (Figure 7b ) and a high s-dTk level was found. (Child et al., 1980, Hagberg et al., In press ) and lactodehydrogenase (Ferraris et al., 1979 , Schneider et al., 1980 . By a recently developed method for quantification of s-dTk in normal serum, variations in s-dTk in NHL patients were detected. The results showed that s-dTk levels in pretreatment sera correlated with the spread of disease, i.e. most patients in stages I and II had normal values, whereas elevated levels, in some cases >100xthe normal value, could be found in sera of patients in stages III and IV. When patients in stages III-IV were divided according to the malignancy of the tumour, it was found that high s-dTk levels, correlated with high malignancy. Discriminant analysis of pretreatment s-dTk levels of patients in stages 111-IV, relative to survival time, revealed two groups which differed significantly in survival time.
The optimal discrimination level of s-dTk was found to be 10 units, with the significant longer survival associated with those having values <10 units. However it could be argued that patients in stages III and IV comprise those with tumours of low malignancy and others with "high grade" malignant tumours. For this reason sera were analysed from a group of patients in stages III and IV who all had "high grade" malignant tumours. The results still showed significantly different survival times for those having s-dTk <10 units compared to those having s-dTk >10 units. Moreover, for stage I-II patients, who received only radiotherapy, a higher relapse frequency was found during the first year when the pretreatment s-dTk level was >5 units. The method may thus be able to identify those patients for whom local radiotherapy cannot be considered sufficient. From the results discussed above it was concluded that pretreatment s-dTk values provide a useful prognostic tool. The prognostic value of s-dTk found in this study is in agreement with a previous smaller study which used another method to determine s-dTk (Ellims et al., 1981b) .
Longitudinal studies of patients with low or high pretreatment values showed that the s-dTk level reflected the activity of the disease; i.e. the titres decreased during tumour regression and increased during tumour progression. For this reason s-dTk C,, 0 -oe can be used to detect relapses. Patients with therapy-resistant or only partially-responsive disease had a persistent elevation of s-dTk. Since sera were always collected before intermittent therapy was administered the long term effects of treatment were mirrored in the s-dTk level. However, the short-to immediate-term effect of successful chemotherapy on s-dTk, as indicated in preliminary studies, is a transient rise (data not shown). The utilization of dTk release as a direct marker for therapic efficacy has been suggested previous from cell cultures studies (Kessel & Wodinsky; , Taylor et al., 1981 .
The origin of the elevated s-dTk is not yet known. We have indicated elsewhere that the serum enzyme is of cellular origin, and probably related to the cytosolar dTk-F (Gronowitz et al., In press ). The enzyme is most likely released into the serum upon the death of cells in a proliferating stage, which seems to be a rare event in healthy individuals. However, the s-dTk level can be increased due to virus infections and pernicious anaemia, but s-dTk is not a marker for non-specific liver damage (Gronowitz et al., In press ). This may, however, be a rare complication since most viruses which are known to give elevated s-dTk, are confined to childhood.
The huge variation in s-dTk found in pretreatment sera of NHL patients considered to have the same clinical picture, could be due to different amounts of dTk per cell in individual tumours or to a higher turnover of the tumour cells. This has to be investigated, as well as how s-dTk expression relates to other better known markers, such as /32-microglobulin and lactodehydrogenase (studies in progress).
The findings reported in this communication show that s-dTk is a prognostic tool and a valuable marker in monitoring the course of the disease in NHL patients. Further, the simplicity of the s-dTk assay makes it suitable for widespread clinical use.
